Publications
PBI-S: Standard version for skin diseases including, among others, acne vulgaris, atopic eczema, and psoriasis vulgaris (long version)
Validation (different skin diseases):
Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schäfer I, Reusch M, Mielke V, Rustenbach SJ: The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 301(8):561-71, 2009.
Validation (psoriasis):
Feuerhahn J, Blome C, Radtke MA, Augustin M. Validation of the Patient Benefit Index for the Assessment of Patient- Relevant Benefit in the Treatment of Psoriasis. Arch Dermatol Res 304 (6):433-41, 2012.
Validation (acne vulgaris):
Augustin M, Reich C, Schaefer I, Zschocke I, Rustenbach SJ: Entwicklung und Validierung eines neuen Instrumentes zur Erfassung patientendefinierten Nutzens in der Therapie der Akne. J Dtsch Dermatol Ges 6(2): 113–20, 2008. — Article is also available in English (Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne). .
Subscales:
Blome C, Augustin M, Behechtnejad J, Rustenbach SJ: Dimensions of Patient Needs in Dermatology: Subscales of the Patient Benefit Index. Arch Dermatol Res 303(1), 11-17, 2011.
PBI 2.0: Short and revised version for skin diseases including atopic dermatitis, psoriasis, ulcus cruris, and vitiligo
Topp J, Augustin M, von Usslar K, Gosau R, Reich K, Reusch M, Blome C (2018). Measuring Patient Needs and Benefits in Dermatology using the ‘Patient Benefit Index 2.0’ – A Validation Study. Acta Derm Venereol. 99(2):211-7, 2019.
PBI-AH: Aged skin
Lohrberg D, Blaak J, Liebsch J, Staib P, Wohlfart R, Lüttje D, Schürer NY, Augustin M, Blome C.Development and Validation of the Patient Benefit Index for the Dermatocosmetic Treatment of Aged Skin. Arch Dermatol Res 308(5):319-24, 2016.
PBI-AR: Allergic rhinitis
Franzke N, Schäfer I, Jost K, Blome C, Rustenbach SJ, Reich K, Reusch M, Maurer M, Augustin M: A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy. May;66(5):665-70, 2011.
PBI-AIT: Allergen immunotherapy treatment of allergic rhinoconjunctivitis
Langenbruch A, Wüstenberg E, Wolf H, Augustin M.: Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy. . Journal of Asthma and Allergy. 15: 611–621, 2022
Demoly P, Aubier M, de Blay F, Wessel F, Clerson P, Maigret P: Evaluation of patients’ expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index – the benefica study. Allergy Asthma Clin Immunol. Feb 26;11(1):8, 2015.
PBI-HE: Chronic hand eczema
Blome C, Maares J, Diepgen T, Rustenbach SJ, Augustin M: Measurement of patient-relevant benefits in the treatment of chronic hand eczema – a novel approach. Contact Dermatitis 61: 39-45, 2009.
PBI-W: Chronic wounds
Augustin M, Blome C, Zschocke I, Schäfer I, Koenig S, Rustenbach SJ, Herberger K: Benefit evaluation in the therapy of chronic wounds from the patients’ perspective-development and validation of a new method. Wound Repair Regen: 20(1):8-14, 2012.
PBI-K: Cosmetic indications
Augustin M, Schäfer I, Rabini S, Lee-Seifert C, Radtke M, Rustenbach SJ: Assessing the value of supportive skin care: development and validation of an instrument for evaluating patient-relevant benefit. Dermatology 218(3):255-9, 2009.
PBI-L: Lymphedema
Blome C, Augustin M, Heyer K, Knöfel J, Cornelsen H, Purwins S, Herberger K: Evaluation of patient-relevant outcomes of lymphedema and lipedema treatment: development and validation of a new benefit tool. Eur J Vasc Endovasc Surg 47(1):100-7, 2013.
Duygu E, Bakar Y, Keser I. An Important Tool in Lymphedema Management: Validation of Turkish Version of the Patient Benefit Index-Lymphedema. Lymphat Res Biol 18(1):49-5, 2020
PBI-MS: Multiple sclerosis
Beckmann H, Augustin M, Heesen C, Poettgen J, Blome C: Benefit evaluation in multiple sclerosis relapse treatment from the patients’ perspective – Development and validation of a new questionnaire. Mult Scler Relat Disord. 28:256-61, 2019
NAPPA-PBI: Nail psoriasis
Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K: Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Development and Validation of a Tool for Assessment of Nail Psoriasis Outcomes. Br J Dermatol 170:591-8, 2014
PBI-POD: Peripheral artery occlusive disease
Zander N, Demirel EB, Augustin M, Sommer R, Debus ES, Breuer P, Blome C (2018). Development and validation of the Patient Benefit Index for peripheral arterial disease. VASA 47(3):219-226, 2018
PBI-P: Pruritus
Blome C, Augustin M, Siepmann D, Phan NQ, Rustenbach SJ, Ständer S. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol 161(5):1143-8, 2009
PBI-Vit: Vitiligo
Augustin M, Gajur AI, Reich C, Rustenbach SJ, Schaefer I. Benefit Evaluation in Vitiligo treatment: Development and Validation of a Patient-Defined Outcomes Questionnaire. Dermatology 217: 101-106, 2008
PBI-S-10: Standard version for skin diseases (10-item short version)
Blome C, von Stülpnagel C, Augustin M, Mrowietz U, Reich K, Muehlan H, Kirsten N, Langenbruch A, Sorbe C, Klein TM (2022). Measuring patient-relevant benefits in psoriasis with the Patient Benefit Index: Development and preliminary validation of a 10-item short form. Br J Dermatol, 2022. [Online ahead of print]
PBI-AR-K
Janke TM, Eisner E, Augustin M, Blome B (2022). Development and validation of a tool for the assessment of benefit from treatment of allergic rhinitis in children and adolescents (PBI AR K). Allergy Asthma Clin Immunol. 18:95, 2022